Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Diakonos Oncology Appoints Laura Aguilar, M.D., Ph.D. as Chief Medical Officer [Yahoo! Finance]
Candel Therapeutics reports Q3 results [Seeking Alpha]
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights